Table 1 Baseline demographics and disease history
Characteristic | Germany (n = 85) | Italy (n = 62) | Spain (n = 31) | UK (n = 45) |
|---|---|---|---|---|
Follow-up time, months, mean (SD) | 10.3 (5.4) | 8.6 (4.8) | 7.1 (5.2) | 7.4 (5.5) |
Female, n (%) | 84 (98.8) | 61 (98.4) | 28 (90.3) | 45 (100.0) |
Ethnic group, n (%) | ||||
White or Caucasian | 85 (100.0) | 61 (98.4) | 30 (96.8) | 44 (97.8) |
Othera | 0 (0.0) | 1 (1.6) | 1 (3.2) | 1 (2.2) |
Age, years, median (range) | 62.0 (40, 81) | 60.0 (36, 83) | 56.0 (38, 79) | 58.0 (32, 92) |
≥ 65 years, n (%) | 34 (40.0) | 21 (33.9) | 11 (35.5) | 17 (37.8) |
ECOG performance status, n (%) | ||||
0 | 27 (31.8) | 18 (29.0) | 6 (19.4) | 14 (31.1) |
1 | 41 (48.2) | 31 (50.0) | 12 (38.7) | 21 (46.7) |
2 | 17 (20.0) | 13 (21.0) | 13 (41.9) | 10 (22.2) |
History of SREsbn (%) | 53 (62.4) | 34 (54.8) | 20 (64.5) | 21 (46.7) |
Time since primary cancer diagnosis, months, median (Q1, Q3) | 70.8 (22.9, 132.2) | 39.0 (8.7, 99.1) | 62.7 (27.5, 138.4) | 72.2 (33.3, 118.0) |
Time since bone metastasis diagnosis, months, median (Q1, Q3) | 4.4 (1.8, 22.9) | 4.1 (1.8, 13.3) | 4.9 (1.8, 39.6) | 9.6 (3.0, 32.2) |